OBJECTIVE: The aim of this study is to present our initial experience in @entity298 treatment and the technical details of @entity1104 ( @entity1104 ) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the light of current literature. MATERIAL AND METHODS: Data of 27 consecutive @entity1 who were treated with @entity1104 and @entity298 in Medical Park Samsun Hospital, between November 2012 and September 2014 were retrospectively reviewed. Treatment indication and management were evaluated at the multidisciplinary oncology council. All @entity1 underwent @entity1104 and HIPEC with the aim of complete cytoreduction. @entity1 with unresectable disease and/or palliative surgery were excluded from analysis. Perioperative complications were classified according to Clavien-Dindo classification, and HIPEC-related side effects were identified using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) criteria. Demographic, clinical and histopathological data of the @entity1 were analyzed. RESULTS: The mean age was 54 (32-72). Nineteen @entity1 were female. The origin of @entity298 was @entity14 in 12 @entity1 , @entity43 in 12 @entity1 , @entity356 in 2 @entity1 and @entity1725 in 1 @entity1 . The mean @entity298 Index was 12 (3-32), with a mean operative time of 420 (300-660) minutes. Perioperative morbidity, HIPEC-related @entity137 and perioperative mortality were observed in eight (30%), one (3.7%) and four @entity1 (14.8%), respectively. During a mean follow up of 13 (1-22) months, overall and disease-free survival rates were 95.8% and 82.6%, respectively. Two @entity1 with @entity14 (after 9 and 12 months) and one @entity1 with @entity43 (after 11 months) had intra-abdominal recurrence. One @entity1 with @entity43 had liver metastases 13 months after surgery, and underwent resection of segments 6-7. The remaining @entity1 are being followed-up without any recurrence. CONCLUSION: Cytoreductive surgery and HIPEC have favorable results in the treatment of @entity1 with @entity298 . Compatible with the literature, surgical outcomes of the presented series are encouraging for this treatment modality that have been recently popularized in our country. Careful perioperative evaluation, proper @entity1 selection and multidisciplinary approach are essential for success in curative treatment of @entity298 .

Cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of XXXX : Our initial experience and technical details.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1725 :: ('MESH:D011553', 'Disease') :: ['pseudomyxoma peritonei'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity1104 :: ('MESH:D000267', 'Disease') :: ['CRS', 'cytoreductive surgery'] @entity298 :: ('MESH:D010538', 'Disease') :: ['HIPEC for peritoneal carcinomatosis', 'peritoneal carcinomatosis', 'Peritoneal Carcinomatosis']
@entity298 :: (MESH:D010538,Disease) :: ['peritoneal carcinomatosis']
